Back

Prognosis in patients with residual pulmonary hypertension after transcatheter edge-to-edge repair for secondary mitral regurgitation

31 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Impact of pulmonary hypertension on quality of life and survival Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hideo Tsubata

Kyoto Prefectural University of Medicine, Kyoto (Japan)

7 More presentations in this session

Presentation thumbnail
Comparison of pulmonary arterial risk assessment tools to predict mortality or morbidity in treatment naive and previously diagnosed patients.
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video
Presentation thumbnail
Prognostic value of follow-up hemodynamics after initial treatment in pulmonary arterial hypertension
Doctor D. Guarino (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Multiparametric risk predictions for morbidity and mortality in patients with pulmonary arterial hypertension: insights from a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease
Doctor R. Takano (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study
Doctor N. Karia (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Impact of pulmonary hypertension on quality of life and survival

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of periprocedural pulmonary hypertension on outcomes after mitral valve transcatheter edge-to-edge repair
thumbnail
Congress Presentation
Impact of pulmonary hypertension on clinical outcomes among patients undergoing transcatheter mitral valve edge to edge repair
thumbnail
Congress Presentation
Residual pulmonary hypertension after PEA - an ill-defined problem

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources